Wils P, et al. - The long-term efficacy and safety of ustekinumab were evaluated in this study. In addition, the researchers identified the predictive factors of ustekinumab failure-free persistence in a cohort of anti-TNF refractory Crohn's disease (CD) patients. With no loss of response, intolerance or surgery and with a good safety profile, more than half of patients continued ustekinumab treatment.